Updates are available Correction dated 2025-05-27
Click to view Correction: https://doi.org/10.1007/s00262-025-04055-7
-
Authors
Ramos-Guerra, Ana D.
Farina, Benito
Rubio Pérez, Jaime
Vilalta-Lacarra, Anna
Zugazagoitia, Jon
Peces-Barba, Germán
Seijo, Luis M.
Paz-Ares, Luis
Gil-Bazo, Ignacio
Dómine Gómez, Manuel
Ledesma-Carbayo, María J.
-
Funding
Funding for this research was provided by:
Agencia Estatal de Investigación (PDC2022-133865-I00)
Fundación BBVA
Instituto de Salud Carlos III (PMP21/00107)
European Commission
Universidad Politécnica de Madrid
- License Information
-
More Information
Article History
Received: 22 October 2024
Accepted: 1 February 2025
First Online: 25 February 2025
Change Date: 27 May 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00262-025-04055-7
Declarations
:
: The authors ADRG, BF, JRP, and MJLC did not report any potential Conflict of interest. AVL declares contracts with AstraZeneca, speaker roles for Health in code, and participation in meetings with AstraZeneca, BMS, and Roche. JZ has served as a consultant for Sanofi, AstraZeneca, BMS, Roche, Pfizer, Novartis, and Guardant Health. He reports speakers’ honoraria from Janssen, Amgen, Sanofi, Takeda, BMS, Pfizer, Roche, Astra Zeneca, Diagnostica Longwood, and NanoString. He reports travel honoraria from Sanofi, Takeda, BMS, Pfizer, Roche, Astra Zeneca, and NanoString. He has received research support/funds from BMS, Astra Zeneca, and Roche. GPB declares grants from GSK, Chiesi, and Menarini, none of them related to the subject of the paper. LMS reports a role as scientific advisor for Sabartech, Serum, Astra Zeneca, Roche, MSD, and Median technologies, and paid honoraria as a speaker from Astra Zeneca, GSK, Roche, Menarini, and Chiesi. LPA declares grants/contracts from MSD, AstraZeneca, Pfizer, and BMS; consulting fees from Eli Lilly, MSD, Roche, Pharmamar, Merck, AstraZeneca, Novartis, Servier, Amgen, Pfizer, Sanofi, Bayer, BMS, Mirati, GSK, Janssen, Takeda, and Daiichi Sankyo; and payment/honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Janssen, Merck, and Mirati. IGB declares advisory board/speaker roles for Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Roche, Johnson & Johnson, MSD, Pfizer, Regeneron, Sanofi, and Takeda. MDG declares consulting/advisory roles for AstraZeneca, Boehringer Ingelheim, Janssen, MSD, Pfizer, Roche, Sanofi, and Takeda; and speaker roles for AstraZeneca, BMS, MSD, Pfizer, Roche, and Takeda.
